Literature DB >> 10467373

pCOR: a new design of plasmid vectors for nonviral gene therapy.

F Soubrier1, B Cameron, B Manse, S Somarriba, C Dubertret, G Jaslin, G Jung, C L Caer, D Dang, J M Mouvault, D Scherman, J F Mayaux, J Crouzet.   

Abstract

A totally redesigned host/vector system with improved properties in terms of safety has been developed. The pCOR plasmids are narrow-host range plasmid vectors for nonviral gene therapy. These plasmids contain a conditional origin of replication and must be propagated in a specifically engineered E. coli host strain, greatly reducing the potential for propagation in the environment or in treated patients. The pCOR backbone has several features that increase safety in terms of dissemination and selection: (1) the origin of replication requires a plasmid-specific initiator protein, pi protein, encoded by the pir gene limiting its host range to bacterial strains that produce this trans-acting protein; (2) the plasmid's selectable marker is not an antibiotic resistance gene but a gene encoding a bacterial suppressor tRNA. Optimized E. coli hosts supporting pCOR replication and selection were constructed. High yields of supercoiled pCOR monomers were obtained (100 mg/l) through fed-batch fermentation. pCOR vectors carrying the luciferase reporter gene gave high levels of luciferase activity when injected into murine skeletal muscle.

Entities:  

Mesh:

Year:  1999        PMID: 10467373     DOI: 10.1038/sj.gt.3300968

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  23 in total

Review 1.  Vectors for gene therapy of cardiovascular disease.

Authors:  J F Dedieu; A Mahfoudi; A Le Roux; D Branellec
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

Review 2.  Nonviral DNA vectors for immunization and therapy: design and methods for their obtention.

Authors:  Ernesto G Rodríguez
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

Review 3.  Rational vector design for efficient non-viral gene delivery: challenges facing the use of plasmid DNA.

Authors:  Juergen Mairhofer; Reingard Grabherr
Journal:  Mol Biotechnol       Date:  2008-06       Impact factor: 2.695

Review 4.  New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials.

Authors:  Gaëlle Vandermeulen; Corinne Marie; Daniel Scherman; Véronique Préat
Journal:  Mol Ther       Date:  2011-08-30       Impact factor: 11.454

Review 5.  Antibiotic-free selection in biotherapeutics: now and forever.

Authors:  Charlotte Mignon; Régis Sodoyer; Bettina Werle
Journal:  Pathogens       Date:  2015-04-03

6.  Intramuscular gene transfer of fibroblast growth factor-1 using improved pCOR plasmid design stimulates collateral formation in a rabbit ischemic hindlimb model.

Authors:  Bernhard Witzenbichler; Abderrahim Mahfoudi; Fabienne Soubrier; Aude Le Roux; Didier Branellec; Heinz-Peter Schultheiss; Jeffrey M Isner
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

7.  Reducible cationic lipids for gene transfer.

Authors:  B Wetzer; G Byk; M Frederic; M Airiau; F Blanche; B Pitard; D Scherman
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

Review 8.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

Review 9.  Molecular-genetic imaging of cancer.

Authors:  Il Minn; Mitchell E Menezes; Siddik Sarkar; Keerthi Yarlagadda; Swadesh K Das; Luni Emdad; Devanand Sarkar; Paul B Fisher; Martin G Pomper
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

10.  Factors affecting plasmid production in Escherichia coli from a resource allocation standpoint.

Authors:  Drew S Cunningham; Richard R Koepsel; Mohammad M Ataai; Michael M Domach
Journal:  Microb Cell Fact       Date:  2009-05-22       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.